To Fly or not to Fly: Stereotactic MR-guided adaptive RadiotherapyEffectively Treats Ultracentral Lung Tumors with Favorable Long-Term Outcomes

[1]  M. Josipovic,et al.  Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  J. Pomp,et al.  Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy , 2021, Acta oncologica.

[3]  I. Lax,et al.  The HILUS-trial - a prospective Nordic multi-center phase II study of ultra-central lung tumors treated with stereotactic body radiotherapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  H. Eich,et al.  Correlating dose variables with local tumor control in stereotactic body radiotherapy for early stage non-small cell lung cancer: A modelling study on 1500 individual treatments. , 2020, International journal of radiation oncology, biology, physics.

[5]  S. Senan,et al.  Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors. , 2020, International journal of radiation oncology, biology, physics.

[6]  T. Zhuang,et al.  Validation of RTOG 0813 Proximal Bronchial Tree Constraints for Pulmonary Toxicity with Stereotactic Body Radiation Therapy for Central Non-Small Cell Lung Cancer. , 2020, International journal of radiation oncology, biology, physics.

[7]  Suresh Senan,et al.  Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors. , 2019, International journal of radiation oncology, biology, physics.

[8]  H. Kim,et al.  Comparison of treatment plans between IMRT with MR-linac and VMAT for lung SABR , 2019, Radiation oncology.

[9]  Anurag K. Singh,et al.  Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Bahig,et al.  Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  D. Yang,et al.  Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis , 2019, International journal of radiation biology.

[12]  Parag J. Parikh,et al.  Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial , 2018, Advances in radiation oncology.

[13]  Liying Zhang,et al.  The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  A. Louie,et al.  SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial. , 2018, Clinical lung cancer.

[15]  A. Louie,et al.  Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk? , 2018, Radiation Oncology.

[16]  J P Cuijpers,et al.  Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  S. Senan,et al.  Outcomes of Hypofractionated High‐Dose Radiotherapy in Poor‐Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  E. Yorke,et al.  Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. , 2016, Practical radiation oncology.

[19]  O. Sauer,et al.  Definition of stereotactic body radiotherapy , 2013, Strahlentherapie und Onkologie.

[20]  M. Corradetti,et al.  Central-airway necrosis after stereotactic body-radiation therapy. , 2012, The New England journal of medicine.

[21]  P. Garrido,et al.  MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. , 2012, Lung cancer.

[22]  Lech Papiez,et al.  Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. , 2009, International journal of radiation oncology, biology, physics.

[23]  Jan Nyman,et al.  Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[25]  E. Smit,et al.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[26]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Suresh Senan,et al.  Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. , 2005, International journal of radiation oncology, biology, physics.

[28]  M. Hoogeman,et al.  Predicting high-grade esophagus toxicity after treating central lung tumors with stereotactic radiotherapy using a Normal Tissue Complication Probability model. , 2019, International journal of radiation oncology, biology, physics.

[29]  G G Hanna,et al.  UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. , 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

[30]  M. Daly,et al.  P2.05-056 Safety of Stereotactic Body Radiotherapy for Central, Ultracentral, and Paramediastinal Lung Tumors , 2017 .